$LNSR

LENSAR (LNSR) Q2 2026 Earnings Call Transcript

LENSAR (LNSR) reported Q2 2026 revenue of $16.5M, up 18%, with recurring revenue growing 20% to $13.7M. Procedure revenue increased 23% to $10.2M, and adjusted EBITDA improved. The company expanded its installed base and market share, with ALLY systems accounting for nearly half of global installations. Management highlighted long-term growth metrics and international expansion plans.

Original reporting
Published Aug 20, 2026, 2:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 2:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
LENSAR (LNSR) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$LNSRBullishMed
01

Why it matters

Earnings beat may trigger short‑term buying pressure, but limited liquidity could cap price move.

02

Market read

Micro‑cap earnings with solid growth; relevance mainly to sector investors.

03

What to watch

Potential regulatory or reimbursement risks in new markets.

Relevance 6/10Novelty 7/10Timing: Q2 2026 earnings release

Background

LENSAR reported its Q2 2026 financial results, highlighting revenue growth and increased recurring revenue from its ALLY laser system.

Company-level read

Ticker impact

$LNSRBullishMedium confidence
Context

Q2 2026 earnings call disclosed 18% revenue growth to $16.5M, 23% recurring revenue increase and strongest adjusted EBITDA to date.

Expected impact

Potential modest upside of 3‑5% as investors digest growth metrics.

Evidence & confidence

Revenue and EBITDA beat expectations for a micro‑cap; however, cash balance fell and scale is limited.

Market effects

Strong growth in cataract‑laser market may benefit peers.

European expansion could boost regional exposure.

Limited to medical device niche.

Counterpoint

Cash burn and modest scale suggest caution despite growth.

Key entities

  • LENSAR

    Medical device maker of cataract laser systems.

Related articles

$LNSRHighAI 9/10

Why is LENSAR stock surging today?

Investing.com reports LENSAR (LNSR) shares rose 16.1% in pre-open after Q2 results beat expectations. The company posted EPS of $0.10 vs consensus -$0.21 and revenue of $16.5M vs $15M. It cited 18% YoY revenue growth, 20% recurring revenue growth, and first positive net income, with 10 ALLY systems placed.

$LNSRMed

LENSAR, Inc. (LNSR): Results of Operations and Financial Condition

LENSAR, Inc. (LNSR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LENSAR ® Reports Second Quarter 2026 Results and Provides Business Update 10 ALLY Robotic Cataract Laser Systems ® (“ALLY System”) Placements in Second Quarter 2026; Backlog of 13 ALLY Systems as of June 30, 2026 Second Quarter Recurring Revenue was $13.7 million Tot

$LNSRMedAI 9/10

Lensar (LNSR) Q4 2025 Earnings Transcript

Lensar reported Q4 2025 revenue of $16 million, down 4% mainly from lower system sales, including weaker sales outside the U.S. The company placed 15 ALLY systems (12 U.S., 1 outside) and grew its installed base to just over 200 ALLY systems (+48%). Recurring revenue rose 17% to $12.7 million (79% of Q4 revenue). Gross margin was 43% ($6.9 million). Management said the Alcon acquisition termination restored independence and full title to a $10 million deposit; 2026 cash operating expenses are ex

$NVDAMedAI 8/10

Nvidia’s Jensen Huang Stands Firm on $4 Trillion AI Bet as Critics Sound Alarms

Nvidia CEO Jensen Huang reaffirmed his forecast of a $3 trillion to $4 trillion AI infrastructure market by 2030, citing strong demand and supply constraints. Nvidia reported $96.2 billion in revenue, exceeding expectations, with data-center sales at $89 billion. Despite warnings from AI leaders about unchecked progress, Huang remains optimistic, pointing to Nvidia's dominant position in the AI sector. Shares slipped Monday amid broader chip stock declines.

$BIOXMed

Bioceres (BIOX) Q4 2026 Earnings Call Transcript

Bioceres (BIOX) reported a challenging fiscal year 2026 with an 18% revenue decline to $238M, driven by seed business reconfiguration and lower crop protection performance. Quarterly revenue was $55.9M, with crop nutrition revenue growing 36%. Adjusted EBITDA improved to $600K from a $9.6M loss, aided by a 19% reduction in SG&A expenses. The company faces litigation and debt restructuring challenges, with total financial debt at $225.9M. Management targets a 40% gross margin for fiscal 2027 and

$PLAYHighAI 8/10

Why Dave & Buster's (PLAY) Stock Is Nosediving

Dave & Buster's (PLAY) stock fell 11.1% after Q2 earnings missed expectations, with revenue of $544.1M (down 2.4% YoY) and an adjusted net loss of $9.5M. Comparable store sales declined 5.0% in June but improved to -1.6% in July. The company's stock is down 59.8% YTD and 71.7% from its 52-week high.